Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450430 · ClinicalTrials.gov registry record · Phase 3
Optimal Timing of Ketamine Initiation for SCD Pain
A Phase 3 study, sponsored by Boston Children's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT07450430 is a Phase 3 study that has not yet begun recruiting, run by Boston Children's Hospital. The registered enrollment target is 90 participants.
The verdict
NCT07450430, a Phase 3 study, has not yet begun recruiting, sponsored by Boston Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain. The main questions this study aims to answer are: * Does ketamine given within 1 hour of acute care presentation decrease the chance of hospital admission? * If admitted, does continuing ketamine in the first few hours of admission decrease opioid use or length of stay compared to those who start it later in the admission? Researchers will compare the study arm to patients with sickle cell disease who receive placebo within 1 hour of presentation for the first aim. Participants will be given ketamine/placebo by mouth without 1 hour of presentation. If admitted, all participants will be able to start open label IV ketamine upon admission to the floor based on their clinical needs. Participants who end up starting ketamine will be reviewed to determine if early start to ketamine is helpful in reducing opioid use and length of stay.
Interventions
- OTHER Placebo
- DRUG Ketamine hydrochloride injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02 |
| Est. Completion | 2030-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07450430
The ClinicalTrials.gov registry entry for NCT07450430 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07450430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07450430 about?
NCT07450430 is a clinical study titled "Optimal Timing of Ketamine Initiation for SCD Pain". The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain. The main questions this study aims to answer are: * Does ketamine given within 1 hour of acute care presentation dec...
What is the current status of trial NCT07450430?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-02. Estimated completion is 2030-02.
What interventions are being tested in trial NCT07450430?
The interventions under investigation include: Placebo (OTHER), Ketamine hydrochloride injection (DRUG).
Who is sponsoring clinical trial NCT07450430?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.